These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36479815)

  • 1. Toxicogenomics Data for Chemical Safety Assessment and Development of New Approach Methodologies: An Adverse Outcome Pathway-Based Approach.
    Saarimäki LA; Morikka J; Pavel A; Korpilähde S; Del Giudice G; Federico A; Fratello M; Serra A; Greco D
    Adv Sci (Weinh); 2023 Jan; 10(2):e2203984. PubMed ID: 36479815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A curated gene and biological system annotation of adverse outcome pathways related to human health.
    Saarimäki LA; Fratello M; Pavel A; Korpilähde S; Leppänen J; Serra A; Greco D
    Sci Data; 2023 Jun; 10(1):409. PubMed ID: 37355733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale.
    Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U
    Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative Data Mining Approach: Case Study with Adverse Outcome Pathway Network Leading to Pulmonary Fibrosis.
    Jeong J; Kim D; Choi J
    Chem Res Toxicol; 2023 Jun; 36(6):838-847. PubMed ID: 37093963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond chemicals: Opportunities and challenges of integrating non-chemical stressors in adverse outcome pathways.
    Clerbaux LA; Filipovska J; Nymark P; Chauhan V; Sewald K; Alb M; Sachana M; Beronius A; Amorim MJ; Wittwehr C
    ALTEX; 2024; 41(2):233-247. PubMed ID: 37980615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment].
    Yamada T; Ashikaga T; Kojima H; Hirose A
    Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring a mechanism-based approach for the identification of endocrine disruptors using Adverse Outcome Pathways (AOPs) and New Approach Methodologies (NAMs) : A perfluorooctane sulfonic acid case study.
    Wiklund L; Pípal M; Weiss J; Beronius A
    Toxicology; 2024 May; 504():153794. PubMed ID: 38580097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of AOPs to assist regulatory assessment of chemical risks - Case studies, needs and recommendations.
    Bajard L; Adamovsky O; Audouze K; Baken K; Barouki R; Beltman JB; Beronius A; Bonefeld-Jørgensen EC; Cano-Sancho G; de Baat ML; Di Tillio F; Fernández MF; FitzGerald RE; Gundacker C; Hernández AF; Hilscherova K; Karakitsios S; Kuchovska E; Long M; Luijten M; Majid S; Marx-Stoelting P; Mustieles V; Negi CK; Sarigiannis D; Scholz S; Sovadinova I; Stierum R; Tanabe S; Tollefsen KE; van den Brand AD; Vogs C; Wielsøe M; Wittwehr C; Blaha L
    Environ Res; 2023 Jan; 217():114650. PubMed ID: 36309218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse outcome pathway: a path toward better data consolidation and global co-ordination of radiation research.
    Chauhan V; Beaton D; Hamada N; Wilkins R; Burtt J; Leblanc J; Cool D; Garnier-Laplace J; Laurier D; Le Y; Yamada Y; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1694-1703. PubMed ID: 34919011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals.
    Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH
    ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high-level overview of the OECD AOP Development Programme.
    Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pragmatic Approach to Adverse Outcome Pathway Development and Evaluation.
    Svingen T; Villeneuve DL; Knapen D; Panagiotou EM; Draskau MK; Damdimopoulou P; O'Brien JM
    Toxicol Sci; 2021 Nov; 184(2):183-190. PubMed ID: 34534351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinoids and developmental neurotoxicity: Utilizing toxicogenomics to enhance adverse outcome pathways and testing strategies.
    Chen H; Chidboy MA; Robinson JF
    Reprod Toxicol; 2020 Sep; 96():102-113. PubMed ID: 32544423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AOPERA: A proposed methodology and inventory of effective tools to link chemicals to adverse outcome pathways.
    Rycroft TE; Foran CM; Thrash A; Cegan JC; Zollinger R; Linkov I; Perkins EJ; Garcia-Reyero N
    ALTEX; 2020; 37(1):64-74. PubMed ID: 31453632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A toxicity pathway-oriented approach to develop adverse outcome pathway: AHR activation as a case study.
    Jin Y; Feng M; Ma W; Wei Y; Qi G; Luo J; Xu L; Li X; Li C; Wang Y; Li D; Chen J; Zhao Y; Hou Y; Zhao Q; Jiang L; Xie M; Zheng Y; Yu D
    Environ Pollut; 2021 Jan; 268(Pt B):115733. PubMed ID: 33011576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation adverse outcome pathways (AOPs) are on the horizon: advancing radiation protection through an international Horizon-Style exercise.
    Burtt JJ; Leblanc J; Randhawa K; Ivanova A; Rudd MA; Wilkins R; Azzam EI; Hecker M; Horemans N; Vandenhove H; Adam-Guillermin C; Armant O; Klokov D; Audouze K; Kaiser JC; Moertl S; Lumniczky K; Tanaka IB; Yamada Y; Hamada N; Al-Nabulsi I; Preston RJ; Bouffler S; Applegate K; Cool D; Beaton D; Tollefsen KE; Garnier-Laplace J; Laurier D; Chauhan V
    Int J Radiat Biol; 2022; 98(12):1763-1776. PubMed ID: 36067511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of evidence-based methods to construct mechanism-driven chemical assessment frameworks.
    Hoffmann S; Aiassa E; Angrish M; Beausoleil C; Bois FY; Ciccolallo L; Craig PS; De Vries RBM; Dorne JLCM; Druwe IL; Edwards SW; Eskes C; Georgiadis M; Hartung T; Kienzler A; Kristjansson EA; Lam J; Martino L; Meek B; Morgan RL; Munoz-Guajardo I; Noyes PD; Parmelli E; Piersma A; Rooney A; Sena E; Sullivan K; Tarazona J; Terron A; Thayer K; Turner J; Verbeek J; Verloo D; Vinken M; Watford S; Whaley P; Wikoff D; Willett K; Tsaioun K
    ALTEX; 2022; 39(3):499–518. PubMed ID: 35258090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AOP-helpFinder webserver: a tool for comprehensive analysis of the literature to support adverse outcome pathways development.
    Jornod F; Jaylet T; Blaha L; Sarigiannis D; Tamisier L; Audouze K
    Bioinformatics; 2022 Jan; 38(4):1173-1175. PubMed ID: 34718414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AOP Report: Inhibition of Chitin Synthase 1 Leading to Increased Mortality in Arthropods.
    Schmid S; Song Y; Tollefsen KE
    Environ Toxicol Chem; 2021 Aug; 40(8):2112-2120. PubMed ID: 33818824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical-induced liver cancer: an adverse outcome pathway perspective.
    Sanz-Serrano J; Callewaert E; De Boever S; Drees A; Verhoeven A; Vinken M
    Expert Opin Drug Saf; 2024 Apr; 23(4):425-438. PubMed ID: 38430529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.